Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. R. Gijtenbeek (Leeuwarden, Netherlands), V. Van Noort (Leeuwarden, Netherlands), J. Aerts (Rotterdam, Netherlands), J. Staal - Van Den Brekel (Almelo / Hengelo, Netherlands), E. Smit (Amsterdam, Netherlands), F. Krouwels (Hoofddorp, Netherlands), F. Wilschut (Ede, Netherlands), T. Hilterman (Groningen, Netherlands), W. Timens (Groningen, Netherlands), E. Schuuring (Groningen, Netherlands), J. Janssen (Endhoven / Veldhoven, Netherlands), M. Goosens (Zutphen, Netherlands), P. Van De Berg (Willemstad, Curaçao), A. De Langen (Amsterdam, Netherlands), J. Stigt (Zwolle, Netherlands), B. Van Den Borne (Eindhoven, Netherlands), H. Groen (Groningen, Netherlands), W. Van Geffen (Leeuwarden, Netherlands), A. Van Der Wekken (Groningen, Netherlands)
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Gijtenbeek (Leeuwarden, Netherlands), V. Van Noort (Leeuwarden, Netherlands), J. Aerts (Rotterdam, Netherlands), J. Staal - Van Den Brekel (Almelo / Hengelo, Netherlands), E. Smit (Amsterdam, Netherlands), F. Krouwels (Hoofddorp, Netherlands), F. Wilschut (Ede, Netherlands), T. Hilterman (Groningen, Netherlands), W. Timens (Groningen, Netherlands), E. Schuuring (Groningen, Netherlands), J. Janssen (Endhoven / Veldhoven, Netherlands), M. Goosens (Zutphen, Netherlands), P. Van De Berg (Willemstad, Curaçao), A. De Langen (Amsterdam, Netherlands), J. Stigt (Zwolle, Netherlands), B. Van Den Borne (Eindhoven, Netherlands), H. Groen (Groningen, Netherlands), W. Van Geffen (Leeuwarden, Netherlands), A. Van Der Wekken (Groningen, Netherlands). Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.. 4324
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019 Year: 2020
Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007
The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007
Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 12s Year: 2005
A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002
Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study Source: Eur Respir J 2003; 22: Suppl. 45, 28s Year: 2003
Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Phase II trial of docetaxel and carboplatin in previously untreated patients with non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Randomized phase III-trial of platinum- vs. non-platinum-based chemotherapy in stage IV non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002
Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009
A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001
Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002